N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia
Status:
Active, not recruiting
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
This study is based on the hypothesis that a new drug N-carbamylglutamate (Carbaglu®) will
enhance the ability of the liver to dispose of toxic ammonia which accumulates in several
metabolic diseases including urea cycle disorders and organic acid disorders.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Mendel Tuchman
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)